UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine

Cephalalgia, 2011-04, Vol.31 (6), p.712-722

2011

Volltextzugriff (PDF)

A phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraine

Cephalalgia, 2016-08, Vol.36 (9), p.887-898

2016

Volltextzugriff (PDF)

Pembrolizumab given concomitantly with chemoradiation and as maintenance therapy for locally advanced head and neck squamous cell carcinoma: KEYNOTE-412

Future oncology (London, England), 2020-06, Vol.16 (18), p.1235-1243

2020

Volltextzugriff (PDF)

Orexin Receptor Antagonism in Painful Diabetic Neuropathy: A Phase 2 Trial With Filorexant

The Clinical journal of pain, 2018-01, Vol.34 (1), p.37-43

2018

Volltextzugriff (PDF)

Pembrolizumab plus epacadostat in patients with recurrent/metastatic head and neck squamous cell carcinoma (KEYNOTE-669/ECHO-304): a phase 3, randomized, open-label study

BMC cancer, 2024-07, Vol.23 (Suppl 1), p.1-12, Article 1254

2024

Volltextzugriff (PDF)

Health-Related Quality of Life with Pembrolizumab in Patients with Locally Advanced or Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma: KEYNOTE-629

Dermatology and therapy, 2023-12, Vol.13 (12), p.3165-3180

2023

Volltextzugriff (PDF)

Reply to “Keynote 48: Is it really for everyone?”

Oral oncology, 2021-01, Vol.112, p.104983-104983, Article 104983

2021

Volltextzugriff (PDF)

Randomized controlled trial of the CGRP receptor antagonist telcagepant for prevention of headache in women with perimenstrual migraine

Cephalalgia, 2016-02, Vol.36 (2), p.148-161

2016

Volltextzugriff (PDF)

351 Pembrolizumab plus lenvatinib vs chemotherapy and lenvatinib monotherapy for recurrent/metastatic head and neck squamous cell carcinoma that progressed on platinum therapy and immunotherapy: LEAP-009

Journal for immunotherapy of cancer, 2020-11, Vol.8 (Suppl 3), p.A376-A376

2020

Volltextzugriff (PDF)

Pembrolizumab plus chemoradiation vs chemoradiation alone for locally advanced head and neck squamous cell carcinoma: The phase 3 KEYNOTE-412 study

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.TPS6094-TPS6094

2018

Volltextzugriff (PDF)

Pembrolizumab Alone or With Chemotherapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma in KEYNOTE-048: Subgroup Analysis by Programmed Death Ligand-1 Combined Positive Score

Journal of clinical oncology, 2022-07, Vol.40 (21), p.2321-2332

2022

Volltextzugriff (PDF)

Phase 1 study of pembrolizumab (pembro; MK-3475) plus ipilimumab (IPI) as second-line therapy for advanced non-small cell lung cancer (NSCLC): KEYNOTE-021 cohort D

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.8011-8011

2015

Volltextzugriff (PDF)

34762 Adjuvant pembrolizumab versus placebo in high-risk locally advanced cutaneous squamous cell carcinoma: The phase 3 KEYNOTE-630 study

Journal of the American Academy of Dermatology, 2022-09, Vol.87 (3), p.AB135-AB135

2022

Volltextzugriff (PDF)

A Two-Stage Adaptive Design in Phase 2 Clinical Trials for Acute Treatment of Migraine

Drug information journal, 2011-05, Vol.45 (3), p.315-330

2011

Volltextzugriff (PDF)

Some Group Sequential Trials from Industry over the Last 30 Years

Statistics in biopharmaceutical research, 2024-07, Vol.16 (3), p.281-293

2024

Volltextzugriff (PDF)

Abstract LB-138: Adjuvant pembrolizumab or placebo in patients with high-risk, locally advanced cutaneous squamous cell carcinoma: Phase 3 KEYNOTE-630

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.LB-138-LB-138

2020

Volltextzugriff (PDF)

KEYNOTE-630: Phase 3 study of adjuvant pembrolizumab versus placebo in patients with high-risk, locally advanced cutaneous squamous cell carcinoma

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.TPS9597-TPS9597

2019

Volltextzugriff (PDF)

Abstract CT285: KEYNOTE-689: A phase 3 study of neoadjuvant and adjuvant pembrolizumab plus standard of care (SOC) in locally advanced (LA) head and neck squamous cell carcinoma (HNSCC)

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.CT285-CT285

2020

Volltextzugriff (PDF)

P-94 Pembrolizumab plus lenvatinib vs chemotherapy and lenvatinib monotherapy for recurrent/metastatic head and neck squamous cell carcinoma that progressed on platinum therapy and immunotherapy: LEAP-009

Oral oncology, 2021-07, Vol.118, p.10-11

2021

Volltextzugriff (PDF)

A phase 3, randomized, open-label study of epacadostat plus pembrolizumab, pembrolizumab monotherapy, and the EXTREME regimen as first-line treatment for recurrent/metastatic head and neck squamous cell carcinoma (R/M SCCHN): ECHO-304/KEYNOTE-669

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.TPS6090-TPS6090

2018

Volltextzugriff (PDF)

KEYNOTE-689: Phase 3 study of adjuvant and neoadjuvant pembrolizumab combined with standard of care (SOC) in patients with resectable, locally advanced head and neck squamous cell carcinoma

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.TPS6090-TPS6090

2019

Volltextzugriff (PDF)

Abstract LB-258: Efficacy of first-line (1L) pembrolizumab by PD-L1 combined positive score <1, 1-19, and ≥20 in recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): KEYNOTE-048 subgroup analysis

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.LB-258-LB-258

2020

Volltextzugriff (PDF)

Abstract CT163: KEYNOTE-412: Pembrolizumab plus chemoradiation vs chemoradiation alone for locally advanced head and neck squamous cell carcinoma

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.CT163-CT163

2018

Volltextzugriff (PDF)

Phase I/II study of pembrolizumab (pembro) plus ipilimumab (ipi) as second-line therapy for NSCLC: KEYNOTE-021 cohorts D and H

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.9027-9027

2016

Volltextzugriff (PDF)

Pembrolizumab in combination with lenalidomide and low-dose dexamethasone for relapsed/refractory multiple myeloma (RRMM): Final efficacy and safety analysis

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.8010-8010

2016

Volltextzugriff (PDF)

1 – 25 von 99

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(89)
Mit Volltextzugriff
(86)

Publikationsform

Sprache

Englisch
(99)
Japanisch
(12)

Erscheinungsjahr

n.n

Thema

Science & Technology
(62)
Life Sciences & Biomedicine
(54)
Humans
(29)
Female
(20)
Male
(18)
Animals
(16)
Biological And Medical Sciences
(14)
Adult
(13)
Medical Sciences
(9)
Mice
(9)
Middle Aged
(9)
Public, Environmental & Occupational Health
(8)
Oncology
(6)
Physical Sciences
(6)
Science & Technology - Other Topics
(6)
Cardiac & Cardiovascular Systems
(5)
Cardiovascular System & Cardiology
(5)
Child
(5)
Child, Preschool
(5)
Children & Youth
(5)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine

A phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraine

Pembrolizumab given concomitantly with chemoradiation and as maintenance therapy for locally advanced head and neck squamous cell carcinoma: KEYNOTE-412

Orexin Receptor Antagonism in Painful Diabetic Neuropathy: A Phase 2 Trial With Filorexant

Pembrolizumab plus epacadostat in patients with recurrent/metastatic head and neck squamous cell carcinoma (KEYNOTE-669/ECHO-304): a phase 3, randomized, open-label study

Health-Related Quality of Life with Pembrolizumab in Patients with Locally Advanced or Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma: KEYNOTE-629

Reply to “Keynote 48: Is it really for everyone?”

Randomized controlled trial of the CGRP receptor antagonist telcagepant for prevention of headache in women with perimenstrual migraine

351 Pembrolizumab plus lenvatinib vs chemotherapy and lenvatinib monotherapy for recurrent/metastatic head and neck squamous cell carcinoma that progressed on platinum therapy and immunotherapy: LEAP-009

Pembrolizumab plus chemoradiation vs chemoradiation alone for locally advanced head and neck squamous cell carcinoma: The phase 3 KEYNOTE-412 study

Pembrolizumab Alone or With Chemotherapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma in KEYNOTE-048: Subgroup Analysis by Programmed Death Ligand-1 Combined Positive Score

Phase 1 study of pembrolizumab (pembro; MK-3475) plus ipilimumab (IPI) as second-line therapy for advanced non-small cell lung cancer (NSCLC): KEYNOTE-021 cohort D

34762 Adjuvant pembrolizumab versus placebo in high-risk locally advanced cutaneous squamous cell carcinoma: The phase 3 KEYNOTE-630 study

A Two-Stage Adaptive Design in Phase 2 Clinical Trials for Acute Treatment of Migraine

Some Group Sequential Trials from Industry over the Last 30 Years

Abstract LB-138: Adjuvant pembrolizumab or placebo in patients with high-risk, locally advanced cutaneous squamous cell carcinoma: Phase 3 KEYNOTE-630

KEYNOTE-630: Phase 3 study of adjuvant pembrolizumab versus placebo in patients with high-risk, locally advanced cutaneous squamous cell carcinoma

Abstract CT285: KEYNOTE-689: A phase 3 study of neoadjuvant and adjuvant pembrolizumab plus standard of care (SOC) in locally advanced (LA) head and neck squamous cell carcinoma (HNSCC)

P-94 Pembrolizumab plus lenvatinib vs chemotherapy and lenvatinib monotherapy for recurrent/metastatic head and neck squamous cell carcinoma that progressed on platinum therapy and immunotherapy: LEAP-009

A phase 3, randomized, open-label study of epacadostat plus pembrolizumab, pembrolizumab monotherapy, and the EXTREME regimen as first-line treatment for recurrent/metastatic head and neck squamous cell carcinoma (R/M SCCHN): ECHO-304/KEYNOTE-669

KEYNOTE-689: Phase 3 study of adjuvant and neoadjuvant pembrolizumab combined with standard of care (SOC) in patients with resectable, locally advanced head and neck squamous cell carcinoma

Abstract LB-258: Efficacy of first-line (1L) pembrolizumab by PD-L1 combined positive score <1, 1-19, and ≥20 in recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): KEYNOTE-048 subgroup analysis

Abstract CT163: KEYNOTE-412: Pembrolizumab plus chemoradiation vs chemoradiation alone for locally advanced head and neck squamous cell carcinoma

Phase I/II study of pembrolizumab (pembro) plus ipilimumab (ipi) as second-line therapy for NSCLC: KEYNOTE-021 cohorts D and H

Pembrolizumab in combination with lenalidomide and low-dose dexamethasone for relapsed/refractory multiple myeloma (RRMM): Final efficacy and safety analysis

Suchergebnisse filtern